Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (845)	5/21/1998 10:19:00 AM
From: wolfdog2	Respond to of 1491

Yosi (and everyone), I wouldn't be surprised to see PARS eventually partner with more than one major pharma for the development of HU211, with each partner helping to develop a different indication.

To: yosi s who wrote (845)	5/21/1998 10:35:00 AM
From: Ariella	Read Replies (1) \| Respond to of 1491

Yosi -- I've read "alternative" websites about HU-211. People have been saying great things about real cannabis (though ours is, of course, manufactured and not grown) because of its ability to stimulate appetite in cancer patients, AIDS patients. They want marijuana to be available to those patients by prescription. Maybe HU-211 is the answer. Sizeable target market mentioned in release: 500 ,000 in US alone. Great detail to include in release since it gives idea of scope of market for drug. Very encouraging news, especially that PARS releases this information before clinical trials. It will really move stock price if they can get over being shy and simply tell investing public about items in the pipeline. Same goes for tamoxifen. A new release should go out about that before the June BIO conference. Regards, Ariella